DIAGMMR®

DIAGNOSTICS INNOVATION

Our mission is to Enable an easy and accurate
Lynch
cancer syndrome detection or exclusion.

Our innovation simplifies early detection of Lynch syndrome,
provides actionable results and can help prevent cancer.

Lynch Syndrome

LYNCH SYNDROME

1 in 279 people have Lynch syndrome, i.e. inherited mismatch repair (MMR) deficiency, making it the most common cause of hereditary cancers.

LS Drop

INHERITED DEFECT

Lynch syndrome (LS) is inherited with 50% probability within affected families. Each single year, more than 2 million new cancer cases should be tested for LS.

LS CancerDiag Microscope

INDIVIDUAL RISK

Individuals with inherited MMR deficiency have an up to 80% risk of developing cancer and at a significantly younger age than the general population.

DiagMMR Tube

INNOVATIVE SOLUTION

DiagMMR® is a simple and accurate test to reliably detect MMR deficiency, supporting the early detection of Lynch syndrome, enabling preventive care and helping save lives.

We .

Invest today!

LS CancerDiag has launched a funding round in collaboration with Springvest

The company aims to raise €5.4M in capital to support the expansion into the United States and introduce DiagMMR® to the largest health care market in the world.